Sanger Sequencing Market Report 2026

The sanger sequencing market size has grown rapidly in recent years. It will grow from $3.29 billion in 2025 to $3.85 billion in 2026 at a compound annual growth rate (CAGR) of 17.1%. The growth in the historic period can be attributed to early adoption of sanger sequencing as the gold standard, increasing academic and government genomics research, growth in genetic disorder testing, expanding use in forensic investigations, rising pharmaceutical research and development activities.

The sanger sequencing market size is expected to see rapid growth in the next few years. It will grow to $7.13 billion in 2030 at a compound annual growth rate (CAGR) of 16.7%. The growth in the forecast period can be attributed to ongoing need for confirmatory sequencing alongside NGS, growth in personalized medicine applications, rising demand for cost-effective targeted sequencing, expanding clinical diagnostics in emerging markets, increased collaborations between biotech firms and research institutes. Major trends in the forecast period include continued use of sanger sequencing for validation of NGS results, steady demand for targeted gene sequencing in diagnostics, growing application in biomarker and cancer research, increasing outsourcing of sequencing services to specialized labs, sustained adoption in forensics and reproductive health testing.

The increasing prevalence of genetic illnesses is expected to drive the growth of the sanger sequencing market in the coming years. Genetic illnesses, or genetic disorders, are medical conditions caused by abnormalities or mutations in an individual’s DNA, the hereditary material that carries genetic information. Sanger sequencing is used to diagnose these conditions by determining the precise order of nucleotides - the building blocks of DNA - in a specific gene or DNA region. For example, in August 2024, the National Health Service, a UK-based publicly funded healthcare system, reported that approximately 2,300 individuals in the UK were living with thalassaemia, with around 800 of them having the severe form of the condition requiring regular blood transfusions. Therefore, the rising prevalence of genetic illnesses is supporting growth in the sanger sequencing market.

Key companies in the sanger sequencing market are focusing on expanding genomic laboratories to provide faster sequencing services in northern regions of the UK. Genomic laboratories are specialized facilities that conduct genetic testing and analysis to study the structure, function, and inheritance of genes and genomes, often for diagnostic, research, or personalized medicine purposes. For instance, in June 2023, Source Genomics, a UK-based genomic services provider, announced the expansion of its laboratory operations into northern UK, enhancing the capacity of its sanger sequencing services and reducing data delivery turnaround times. This expansion represents a major step in improving equitable access to genomic services across the country, allowing research organizations and customers nationwide to benefit from high-quality sanger sequencing with faster results.

In January 2023, Qiagen, a Germany-based provider of sample and assay technologies, acquired Verogen for $150 million. This acquisition enables Qiagen to optimize its market-leading capabilities in sample extraction and library preparation automation while expanding both companies’ channel reach and presence in the forensic market. Verogen, based in the US, provides sanger sequencing solutions for human identification and forensic laboratories.

Major companies operating in the sanger sequencing market are Hoffmann La Roche, Thermo Fisher Scientific Inc, Merck KGaA, Eurofins Scientific, Beckman Coulter, PerkinElmer Inc, LGC Limited, GenScript, Macrogen Inc, GENEWIZ Inc, Quintara Biosciences, CeMIA SA, Source BioScience, Microsynth AG, Fasteris SA, GenHunter Corporation, Nucleics Pty Ltd, SciGenom Labs Pvt Ltd, StarSEQ GmbH, GATC Biotech AG, Agilent Technologies, Azenta Life Sciences, CD Genomics, Novogene Sanger Services.

North America was the largest region in the sanger sequencing market in 2025. The regions covered in the sanger sequencing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sanger sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the Sanger sequencing market by increasing costs of imported sequencing instruments, reagents, capillary electrophoresis components, and laboratory consumables. Research-intensive regions such as North America and Europe are most affected due to dependence on globally sourced sequencing platforms, while Asia-Pacific faces higher procurement costs for reagents. These tariffs may raise operational expenses for laboratories. At the same time, they are driving local reagent production, regional instrument assembly, and investment in cost-efficient sequencing workflows.

The sanger sequencing market research report is one of a series of new reports that provides sanger sequencing market statistics, including sanger sequencing industry global market size, regional shares, competitors with a sanger sequencing market share, detailed sanger sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the sanger sequencing industry. This sanger sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Sanger sequencing, also known as chain termination sequencing, is a technique used to determine the nucleotide sequence of DNA. It is commonly employed for smaller-scale projects and for validating results from deep sequencing, as it can generate DNA sequence reads exceeding 500 nucleotides while maintaining high accuracy.

The main types of Sanger sequencing include shotgun sequencing, targeted gene sequencing, and others. In shotgun sequencing, random fragments of a long DNA molecule are sequenced in parallel and later assembled based on overlapping regions. The sequencing is conducted in various laboratory settings, including wet labs and dry labs, and research can be performed in-house or outsourced. Sanger sequencing is applied in areas such as diagnostics, biomarkers and cancer research, reproductive health, personalized medicine, forensics, and more. End users include academic institutions, government research institutes, pharmaceutical and biotechnology companies, hospitals, and clinics.

The sanger sequencing market includes revenues earned by entities by providing DNA synthesis, and targeted synthesis. The market value includes the value of related goods sold by the service provider or included within the service offering.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.